mp.weixin.qq.com·· 15 hours agoPickScore76
NMPA Approves Bio-Thera's Secukinumab Biosimilar Youzhuomei (BAT2306)
In brief
Bio-Thera announced that the NMPA has approved Youzhuomei (BAT2306), a biosimilar of secukinumab, for psoriasis, ankylosing spondylitis, and psoriatic arthritis. The anti-IL-17A monoclonal antibody is described by the company as the world's first approved secukinumab biosimilar, and it has been licensed to multiple partners covering markets including the Middle East and North Africa, Latin America, Southeast Asia, Russia, and the CIS.
Why it matters
The approval specifies indications and target and discloses licensed overseas regions, aiding assessment of domestic access and global commercialization.
Source: mp.weixin.qq.com · mp.weixin.qq.com